Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis

Journal of Rheumatology

Volumn 30, Issue 7, 2003, Pages 1541-1547

  Zhou, Yihua ^b   Huang, Deren ^b   Farver, Carol ^b   Hoffman, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

CCR5; Chemokines; Receptors chemokines polymorphisms; Wegener's granulomatosis

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR5; GENOMIC DNA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEUTROPHIL CYTOPLASMIC ANTIBODY; RANTES;

ARTICLE; CAUCASIAN; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY DYSFUNCTION; LIGAND BINDING; LUNG BIOPSY; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TISSUE INJURY; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RANTES; RECEPTORS, CCR5; WEGENER GRANULOMATOSIS;

EID: 0037490981     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Gross WL, Trabandt A, Csernok E. Pathogenesis of Wegener's granulomatosis. Ann Med Interne Paris 1998;149:280-6.
2. Hoffman GS. "Wegener's granulomatosis": the path traveled since 1931. Medicine Baltimore 1994;73:325-9.
3. Falk RJ, Jennette JC. Wegener's granulomatosis, systemic vasculitis, and antineutrophil cytoplasmic autoantibodies. Annu Rev Med 1991;42:459-69.
4. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
5. Muller Kobold AC, Kallenberg CG, Tervaert JW. Monocyte activation in patients with Wegener's granulomatosis. Ann Rheum Dis 1999;58:237-45.
6. Csernok E, Trabandt A, Muller A, et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999;42:742-50.
7. Ludviksson BR, Sneller MC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-9.
8. Schlesier M, Kaspar T, Gutfleisch J, Wolff-Vorbeck G, Peter HH. Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. Rheumatol Int 1995;14:213-9.
9. Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med 1983;74:700-4.
10. Muller A, Trabandt A, Gloeckner-Hofmann K, et al. Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J Pathol 2000;192:113-20.
11. Lamprecht P, Moosig F, Csernok E, et al. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 2001;56:751-7.
12. Komocsi A, Lamprecht P, Csernok E, et al. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am J Pathol 2002;160:1717-24.
13. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-9.
14. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Bull Rheum Dis 1998;47:5-8.
15. Rao JK, Allen NB, Feussner JR, Weinberger M. A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis. Lancet 1995;346:926-31.
16. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis. Adv Exp Med Biol 1993;336:411-4.
17. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
18. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76.
19. Baggiolini M. Chemokines and leukocyte, traffic. Nature 1998;392:565-8.
20. Bacon KB, Premack BA, Gardner P, Schall TJ. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995;269:1727-30.
21. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-71.
22. Cameron MJ, Arreaza GA, Grattan M, et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 2000;165:1102-10.
23. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999;96:6873-8.
24. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
25. Huang D, Han Y, Rani MR, et al. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev 2000;177:52-67.
26. Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-5.
27. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998;101:746-54.
28. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83.
29. Aliberti J, Sousa C, Schito M, et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 2000;1:83-7.
30. Zou W, Borvak J, Marches F, et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol 2000;165:4388-96.
31. Huffnagle GB, McNeil LK, McDonald RA, et al. Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999;163:4642-6.
32. Sato N, Kuziel WA, Melby PC, et al. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J Immunol 1999;163:5519-25.
33. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8.
34. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48.
35. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
36. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
37. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
38. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997;16:100-3.
39. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-91.
40. Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998;25:1462-5.
41. Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. Association of CCR5 Δ32 with reduced risk of asthma. Lancet 1999;354:1264-5.
42. Barcellos LF, Schito AM, Rimmler JB, et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Immunogenetics 2000;51:281-8.
43. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000;102:98-106.
44. Gomez-Reino JJ, Pablos JL, Carreira PE, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999;42:989-92.
45. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
46. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 1999;96:4581-5.
47. Nickel RG, Casolaro V, Wahn U, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000;164:1612-6.
48. Fryer AA, Spiteri MA, Bianco A, et al. The -403 G→A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immunol 2000;1:509-14.
49. Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998;102:2146-55.
50. Coulomb-L'Hermine A, Capron F, et al. Expression of the chemokine RANTES in pulmonary Wegener's granulomatosis. Hum Pathol 2001;32:320-6.
51. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000;14:2671-8.
52. Tomer Y, Gilburd B, Blank M, et al. Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice. Pathogenetic role in experimental vasculitis. Arthritis Rheum 1995;38:1375-81